Revance Therapeutics Inc. Watch

from 8-K 14 pages Amended and Restated Tender and Support Agreement

from 10-Q 4 pages Fifth Amendment to the Exclusive Distribution Agreement Dated January 10, 2020 Teoxane SA (The Supplier) Rue De Lyon 105, Ch-1203 Geneva, Switzerland and Revance Therapeutics Inc. (The Distributor) 7555 Gateway Boulevard Newark, California, USA

from 10-Q 5 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because Revance Therapeutics, Inc., Has Determined the Information (I) Is Not Material and (II) Is the Type That Revance Therapeutics, Inc. Treats as Private and Confidential

from 8-K 40 pages Exclusive Distribution Agreement

from 8-K 12 pages Material contract

from 10-Q 2 pages Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 10-Q 4 pages We Are Pleased to Offer You the Position of Senior Vice President, Strategy at Revance (The “Company”), Reporting Directly to Dustin Sjuts, President. We Look Forward to the Significant Contributions You Will Make at Revance as We Continue to Grow and Advance Our People and Culture Agenda That You Will Lead and Shape. the Following Outlines the Terms of Your Employment Offer Discussed Today. Start Date Your Tentative Start Date Will Be March 31, 2023. Compensation Your Annual Base Salary for This Position Will Be $410,000 Less Payroll Deductions and All Required Withholdings, and Payable on the Company’s Regular Semi-Monthly Payroll Schedule. Annual Incentive Plan

from 10-Q 4 pages Subject to Approval by Compensation Committee of the Board, We Are Pleased to Offer You the Position of Chief Medical Officer at Revance (The “Company”), Reporting Directly to Dustin Sjuts, President. We Look Forward to the Significant Contributions You Will Make to Revance. the Following Outlines the Terms of Your Employment: Start Date Your Target Start Date Will Be October 17, 2022 With the Exact Date to Be Determined by Mutual Agreement. Compensation Your Semi-Monthly Base Salary for This Position Will Be $19,791.67 (Equivalent to $475,000 on an Annualized Basis) Less Payroll Deductions and All Required Withholdings, and Payable on the Company’s Regular Semi-Monthly Payroll Schedule. Annual Incentive Plan

from 10-K 1 page Revance Therapeutics, Inc. 2024 Management Bonus Program

from 8-K 16 pages Re: Separation Agreement Dear Dustin: This Letter Sets Forth the Substance of the Mutual Separation Agreement (The “Agreement”) That Revance Therapeutics, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition

from 8-K 4 pages Amendment No. 2 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement

from 8-K 23 pages Revance Therapeutics, Inc. Executive Severance Benefit Plan Amended and Restated Effective February 7, 2024

from 10-Q 156 pages Material contract

from 10-Q 2 pages March 22, 2023 Re: Second Letter Amendment to the License Agreement

from 10-Q 6 pages Third Amendment to Lease

from 10-Q 5 pages First Addendum to License and Service Agreement

from 10-Q 17 pages License and Service Agreement

from 10-K 5 pages Preamble Now Therefore the Parties Agree to Modify the Exclusive Distribution Agreement as Follows

from 10-K 1 page Revance Therapeutics, Inc. 2023 Management Bonus Program

from 10-K 9 pages Sell to Cover Rsu Grant Package Revance Therapeutics, Inc. Restricted Stock Unit Grant Notice